The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
Open accessAbstract
Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or acquired resistance severely limit the clinical application of platinum-based treatment. The underlying mechanisms are incredibly complicated. Multiple transporters participate in the active transport of platinum-based antitumor agents, and the altered expression level, localization, or activity may severely decrease the cellular platinum accumulation. Detoxification components, which are commonly increasing in resistant tumor cells, can efficiently bind to platinum agents and prevent the formation of platinum-DNA adducts, but the adducts production is the determinant step for the cytotoxicity of platinum-based antitumor agents. Even if adequate adducts have formed, tumor cells still manage to survive through increased DNA repair processes or elevated apoptosis threshold. In addition, autophagy has a profound influence on platinum resistance. This review summarizes the critical participators of platinum resistance mechanisms mentioned above and highlights the most potential therapeutic targets or predicted markers. With a deeper understanding of the underlying resistance mechanisms, new solutions would be produced to extend the clinical application of platinum-based antitumor agents largely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Sun, J. F., Cai, X., Yung, M. M. H., Zhou, W., Li, J., Zhang, Y., Li, Z., Liu, S. S., Cheung, A., Ngan, H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0459-x · Cited by 142
RetractedSun, J., Pan, L.-M., Chen, L., & Wang, Y. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1361071 · Cited by 71
Self-citationRetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Glutathione in Cancer Biology and Therapy
Estrela, J. M., Ortega, A., & Obrador, E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500523878 · Cited by 1,041
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Protein Turnover Via Autophagy: Implications for Metabolism
Mizushima, N., & Klionsky, D. J. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093749 · Cited by 792
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Oxidative Stress Is Inherent in Prostate Cancer Cells and Is Required for Aggressive Phenotype
Kumar, B., Koul, S., Khandrika, L., Meacham, R. B., & Koul, H. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5259 · Cited by 736
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
Tumor microenvironment: The role of the tumor stroma in cancer
Li, H., Fan, X., & Houghton, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21159 · Cited by 646
Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision Repair
Gillet, L. C. J., & Schärer, O. D. (2006) · Chemical Reviews · doi:10.1021/cr040483f · Cited by 642 · cited 4×
“ERCC4 (XPF), a necessary component in NER, interstrand cross-links repair, homologous recombination repair (HRR) but not in nonhomologous end-joining (Lehmann et al., 2017), contributes to the intrinsic resistance of cisplatin, and its expression level is tissue-specific (Zhang et al., 2016a).”
BackgroundInfluentialZheng, P., Chen, L., Yuan, X., Luo, Q., Liu, Y., Xie, G., Ma, Y., & Shen, L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0528-y · Cited by 629
Self-citationNorquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Bruno, P. M., Liu, Y., Park, G. Y., Murai, J., Koch, C. E., Eisen, T. J., Pritchard, J. R., Pommier, Y., Lippard, S. J., & Hemann, M. T. (2017) · Nature Medicine · doi:10.1038/nm.4291 · Cited by 519
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Taniguchi, K., WADA, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S.-I., & Kuwano, M. (1996) · PubMed · Cited by 470
Dalby, K., Tekedereli, I., Lopez-Berestein, G., & Ozpolat, B. (2010) · Autophagy · doi:10.4161/auto.6.3.11625 · Cited by 446
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch-Shimon, S., Kaufman, B., Gershoni-Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 436
Qin, X., Guo, H., Wang, X., Zhu, X., Yan, M., Wang, X., Xu, Q., Shi, J., Lu, E., Chen, W., et al. (2019) · Genome Biology · doi:10.1186/s13059-018-1604-0 · Cited by 431
ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein.
Jedlitschky, G., Leier, I., Buchholz, U., M Center, & KEPPLER, D. O. R. (1994) · PubMed · Cited by 426
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Self-citationThe Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective
Kimura, T., & Kambe, T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030336 · Cited by 409
Nagao, A., Kobayashi, M., Koyasu, S., Chow, C. C. T., & Harada, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020238 · Cited by 402
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Jennis, M., Kung, C.-P., Basu, S., Budina-Kolomets, A., Leu, J. I.-J., Khaku, S., Scott, J. P., Cai, K. Q., Campbell, M. R., Porter, D. K., et al. (2016) · Genes & Development · doi:10.1101/gad.275891.115 · Cited by 352
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., & Inui, K.-I. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110346 · Cited by 344
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy
Keppler, D. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_8 · Cited by 318
Oxaliplatin-Induced Damage of Cellular DNA
Woynarowski, J. M., Faivre, S., Herzig, M. C. S., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12463-7 · Cited by 310
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
Therapy resistance mediated by cancer stem cells
Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I.-I. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.006 · Cited by 286
Choi, Y.-M., Kim, H.-K., Shim, W., Anwar, M. A., Kwon, J.-W., Kwon, H.-K., Kim, H. J., Jeong, H., Kim, H. M., Hwang, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135083 · Cited by 279
Human Copper Transporters: Mechanism, Role in Human Diseases and Therapeutic Potential
Gupta, A., & Lutsenko, S. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.84 · Cited by 275
Hypoxia-inducible factor 3 biology: complexities and emerging themes
Duan, C. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00315.2015 · Cited by 269 · cited 1×
“HIF1a and HIF2a are widely expressed in various tissues and have been well understood, yet HIF3a is less known due to its high specificity of tissue distribution and the existence of multiple variants (Duan, 2016).”
BackgroundBrozovic, A., Ambriović-Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 261
Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., & Kuo, M. T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1543.3.12 · Cited by 259
Current status of the molecular mechanisms of anticancer drug-induced apoptosis
Kim, R., Tanabe, K., Uchida, Y., Emi, M., Inoue, H., & Toge, T. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0522-7 · Cited by 253
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251 · cited 1×
“Whereas under hypoxic conditions, impaired hydroxylation process stabilizes the HIF1a protein, furthermore HIF1a will translocate into nuclear and dimerize with HIF1b to transactivate the target genes which relate with glucose metabolism, angiogenesis, cell proliferation, invasion and metastasis (reviewed in Pawlus an…”
BackgroundYokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T., & Inui, K.-I. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.004 · Cited by 250
Impaired Glutathione Synthesis in Neurodegeneration
Aoyama, K., & Nakaki, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021021 · Cited by 226
Classification Systems of Secondary Active Transporters
Perland, E., & Fredriksson, R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.008 · Cited by 224
Drayton, R. M., Dudziec, E., Peter, S., Bertz, S., Hartmann, A., Bryant, H. E., & Catto, J. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2805 · Cited by 220
van den Berghe, P. V. E., Folmer, D. E., Malingré, H. E. M., van Beurden, E., Klomp, A. E. M., van de Sluis, B., Merkx, M., Berger, R., & Klomp, L. W. J. (2007) · Biochemical Journal · doi:10.1042/bj20070705 · Cited by 217
Pan, J., Li, X., Wu, W., Xue, M., Hou, H., Zhai, W., & Chen, W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.015 · Cited by 216
DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells
Faivre, S., Chan, D., Salinas, R., Woynarowska, B., & Woynarowski, J. M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00260-0 · Cited by 211
Hung, J.-J., Yang, M.-H., Hsu, H.-S., Hsu, W.-H., Liu, J.-S., & Wu, K.-J. (2009) · Thorax · doi:10.1136/thx.2009.115691 · Cited by 207
Self-citationFang, Z., Zhao, J., Xie, W., Sun, Q., Wang, H., & Qiao, B. (2017) · Cancer Medicine · doi:10.1002/cam4.1253 · Cited by 207
Self-citationZhang, X.-W., Bu, P., Liu, L., Zhang, X.-Z., & Li, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.121 · Cited by 202
Cruz-Bermúdez, A., Laza-Briviesca, R., Vicente-Blanco, R. J., García-Grande, A., Coronado, M. J., Laine-Menéndez, S., Palacios-Zambrano, S., Moreno-Villa, M. R., Ruiz-Valdepeñas, A. M., Lendinez, C., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.009 · Cited by 196
Ai, Z., Lu, Y., Qiu, S., & Fan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.009 · Cited by 195
Chang, C.-H., Lee, C.-Y., Lu, C.-C., Tsai, F.-J., Hsu, Y.-M., Tsao, J.-W., Juan, Y.-N., Chiu, H.-Y., Yang, J.-S., & Wang, C.-C. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3866 · Cited by 192
Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
Ma, M.-Z., Chen, G., Wang, P., Lu, W.-H., Zhu, C.-F., Song, M., Yang, J., Wen, S., Xu, R.-H., Hu, Y., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.031 · Cited by 186
Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., & Patrick, S. M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.010 · Cited by 182
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
Zhu, Z., Du, S., Du, Y., Ren, J., Ying, G., & Yan, Z. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14250 · Cited by 175
Cheng, C., Qin, Y., Zhi, Q., Wang, J., & Qin, C. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.10.154 · Cited by 166
Rocha, C. R. R., Garcia, C. C. M., Vieira, D. B., Quinet, A., de Andrade-Lima, L. C., Munford, V, Belizário, J. E., & Menck, C. F. M. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.465 · Cited by 164
Li, Q., Yu, J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., Bostick-Bruton, F., & Reed, E. (2000) · PubMed · Cited by 161
Lung cancer stem cells: The root of resistance
MacDonagh, L., Gray, S. G., Breen, E. P., Cuffe, S. D., Finn, S. P., O'Byrne, K. J., & Barr, M. P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.012 · Cited by 161
GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy
Kim, M., Jung, J.-Y., Choi, S., Lee, H., Morales, L. D., Koh, J.-T., Kim, S. H., Choi, Y.-D., Choi, C., Slaga, T. J., et al. (2017) · Autophagy · doi:10.1080/15548627.2016.1239676 · Cited by 160
Samimi, G., Katano, K., Holzer, A. K., Safaei, R., & Howell, S. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.25 · Cited by 158
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4Preprint
Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015) · Genes & Development · doi:10.1101/gad.256214.114 · Cited by 157
Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy
Shteingauz, A., Boyango, I., Naroditsky, I., Hammond, E., Gruber, M., Doweck, I., Ilan, N., & Vlodavsky, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0037 · Cited by 156
Rohwer, N., Dame, C., Haugstetter, A., Wiedenmann, B., Detjen, K. M., Schmitt, C. A., & Cramer, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012038 · Cited by 154
Blair, B. G., Larson, C., Safaei, R., & Howell, S. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0311 · Cited by 154
Autophagic control of cell ‘stemness’
Pan, H., Cai, N., Li, M., Liu, G., & Belmonte, J. C. I. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201999 · Cited by 153
Li, B., Wang, W., Li, Z., Chen, Z., Zhi, X., Xu, J., Li, Q., Wang, L., Huang, X., Wang, L., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.035 · Cited by 153
Wang, Z., Deng, Z., & Zhu, G. (2019) · Dalton Transactions · doi:10.1039/c8dt03923b · Cited by 153
Crystal Structures of Cisplatin Bound to a Human Copper Chaperone
Boal, A. K., & Rosenzweig, A. C. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906363t · Cited by 149
Zheng, Z., Xu, H., Suo, S., Xu, X., Ni, M., Gu, L., Chen, W., Wang, L., Zhao, Y., Tian, B., et al. (2016) · Scientific Reports · doi:10.1038/srep26093 · Cited by 143
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 140
The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure
Holzer, A. K., & Howell, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1710 · Cited by 140
A phosphotyrosine switch regulates organic cation transporters
Sprowl, J. A., Ong, S. S., Gibson, A. A., Hu, S., Du, G., Lin, W., Li, L., Bharill, S., Ness, R. A., Stecuła, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms10880 · Cited by 140
Tao, L., Huang, G., Wang, R., Pan, Y., He, Z., Chu, X., Song, H., & Chen, L. (2016) · Scientific Reports · doi:10.1038/srep38408 · Cited by 137
Self-citationTargeting Autophagy to Overcome Drug Resistance in Cancer Therapy
Kumar, A., Singh, U. K., & Chaudhary, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.88 · Cited by 136
LncRNA HOXA11‐AS drives cisplatin resistance of human LUAD cells via modulating miR‐454‐3p/Stat3
Zhao, X., Li, X., Zhou, L., Ni, J., Yan, W., Ma, R., Wu, J., Feng, J., & Chen, P. (2018) · Cancer Science · doi:10.1111/cas.13764 · Cited by 136
Dai, C.-X., Gao, Q., Qiu, S., Ju, M., Cai, M., Xu, Y., Zhou, J., Zhang, B., & Fan, J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-418 · Cited by 134
Self-citationDann, R. B., DeLoia, J. A., Timms, K. M., Zorn, K. K., Potter, J., Flake, D. D., Lanchbury, J. S. S., & Krivak, T. C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.006 · Cited by 129
Gadhikar, M. A., Sciuto, M. R., Alves, M. V. O., Pickering, C. R., Osman, A. A., Neskey, D. M., Zhao, M., Fitzgerald, A. L., Myers, J. N., & Frederick, M. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0157 · Cited by 129
USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response
Li, Y., Luo, K., Yin, Y., Wu, C., Deng, M., Li, L., Chen, Y., Nowsheen, S., Lou, Z., & Yuan, J. (2017) · Nature Communications · doi:10.1038/ncomms15752 · Cited by 127
Burger, H., Zoumaro-Djayoon, A. D., Boersma, A., Helleman, J., Berns, E., Mathijssen, R. H. J., Loos, W., & Wiemer, E. A. C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00569.x · Cited by 122
Osada, R., Horiuchi, A., Kikuchi, N., Yoshida, J., Hayashi, A., Ota, M., Katsuyama, Y., Mellilo, G., & Konishi, I. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.02.010 · Cited by 121
Kalayda, G. V., Wagner, C. H., Buß, I., Reedijk, J., & Jaehde, U. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-175 · Cited by 120
Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer
Miow, Q. H., Tan, T. Z., Ye, J., Lau, J. A., Yokomizo, T., Thiery, J.-P., & Mori, S. (2015) · Oncogene · doi:10.1038/onc.2014.136 · Cited by 117
Yu, L., Gu, C., Zhong, D., Shi, L., Kong, Y., Zhou, Z., & Liu, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.020 · Cited by 117
Self-citationFoulkes, W. D., & Shuen, A. Y. (2013) · The Journal of Pathology · doi:10.1002/path.4205 · Cited by 117
Transport of Cisplatin by the Copper Efflux Transporter ATP7B
Safaei, R., Otani, S., Larson, B. J., Rasmussen, M. L., & Howell, S. B. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040980 · Cited by 114
miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy
Tan, S., Shi, H., Ba, M., LIN, S., Tang, H., Zeng, X., & Zhang, X. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2492 · Cited by 111
Beretta, G. L., Benedetti, V., Cossa, G., Assaraf, Y. G., Bram, E. E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S. B., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.002 · Cited by 110
Naik, P. P., Mukhopadhyay, S., Panda, P. K., Sinha, N., Das, C. K., Mishra, R., Patil, S., & Bhutia, S. K. (2017) · Cell Proliferation · doi:10.1111/cpr.12411 · Cited by 110
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 108
ABCF2 , an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells
Bao, L., Wu, J., Dodson, M. B., de la Vega, E. M. R., Ning, Y., Zhang, Z., Yao, M., Zhang, D. D., Xu, C., & Yi, X. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22615 · Cited by 106
Byun, S., Kim, S. W., Choi, H., Lee, C., & Lee, E. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05472.x · Cited by 105
Zhen, Y., Fang, W., Zhao, M., Luo, R., Liu, Y., Fu, Q., Chen, Y., Cheng, C., Zhang, Y., & Liu, Z. (2016) · Oncogene · doi:10.1038/onc.2016.201 · Cited by 105
Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin
Liu, Y., Zheng, X., Yu, Q., Wang, H., Tan, F.-Q., Zhu, Q., Yuan, L., Jiang, H., Yu, L., & Zeng, S. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3124 · Cited by 105
Self-citationXi, Z., Si, J., & Nan, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4609 · Cited by 104
Surowiak, P., Materna, V., Kaplenko, I., Spaczyński, M., Dolińska-Krajewska, B., Gębarowska, E., Dietel, M., Zabel, M., & Lage, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0564 · Cited by 103
Wang, X., Jiang, P., Wang, P., Yang, C. S., Wang, X., & Feng, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125402 · Cited by 100
Al-Minawi, A. Z., Lee, Y.-F., Hakansson, D., Johansson, F., Lundin, C., Saleh-Gohari, N., Schultz, N. D., Jenssen, D., Bryant, H. E., Meuth, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp705 · Cited by 97
Spada, F., Antonuzzo, L., Marconcini, R., Radice, D., Antonuzzo, A., Ricci, S., Costanzo, F. D., Fontana, A., Gelsomino, F., Luppi, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000444087 · Cited by 95
Goodspeed, A. E., Jean, A., & Costello, J. C. (2018) · European Urology · doi:10.1016/j.eururo.2018.10.040 · Cited by 94
Gong, T., Cui, L., Wang, H., Wang, H., & Han, N. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1543-2 · Cited by 93
Self-citationSun, C., Wang, F., Zhang, H.-G., Xu, X., Jia, R., Yao, L., & Qiao, P. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i10.1816 · Cited by 92
Pan, Y., Zhang, Q., Atsaves, V., Yang, H., & Claret, F. X. (2012) · Oncogene · doi:10.1038/onc.2012.294 · Cited by 91
Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent
Fu, S., Naing, A., Fu, C., Kuo, M. T., & Kurzrock, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0864 · Cited by 90
Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links
Sawant, A., Kothandapani, A., Zhitkovich, A., Sobol, R. W., & Patrick, S. M. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.10.003 · Cited by 88
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
Kim, E. S., Tang, X., Peterson, D. R., Kilari, D., Chow, C.-W. B., Fujimoto, J., Kalhor, N., Swisher, S. G., Stewart, D. J., Wistuba, I. I., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.04.005 · Cited by 88
CRISPR-Cas9–based target validation for p53-reactivating model compounds
Wanzel, M., Vischedyk, J. B., Gittler, M. P., Gremke, N., Seiz, J. R., Hefter, M., Noack, M., Savai, R., Mernberger, M., Charles, J. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1965 · Cited by 88
Pawlus, M. R., & Hu, C. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.018 · Cited by 87
Sullivan, I., Salazar, J., Majem, M., Pallarés, C., del Río, E., Páez, D., Baiget, M., & Barnadas, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.023 · Cited by 86
van Jaarsveld, M. T. M., van Kuijk, P. F., Boersma, A. W. M., Helleman, J., van IJcken, W. F. J., Mathijssen, R. H. J., Pothof, J., Berns, E. M. J. J., Verweij, J., & Wiemer, E. A. C. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0464-4 · Cited by 84
Huang, F., Chen, H., Zheng, F., Gao, Z., Sun, P., Peng, Q., Liu, Y., Deng, X., Huang, Y., Zhao, C., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4614 · Cited by 84
Mitochondria and reactive oxygen species in renal cancer
Hervouet, É., Simonnet, H., & Godinot, C. (2007) · Biochimie · doi:10.1016/j.biochi.2007.03.010 · Cited by 83
Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy
Wang, J., Zhou, J.-Y., Kho, D., Reiners, J. J., & Wu, G. S. (2016) · Autophagy · doi:10.1080/15548627.2016.1203483 · Cited by 82
Self-citationFukuda, T., Oda, K., Wada‐Hiraike, O., Sone, K., Inaba, K., Ikeda, Y., Miyasaka, A., Kashiyama, T., Tanikawa, M., Arimoto, T., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.053 · Cited by 82
Liu, W., Zhang, Z., Zhang, Y., Chen, X., Guo, S., Yi, L., Xu, Y., Ji, C., Zhi-gang, B., & Wang, K. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1017691 · Cited by 81
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
Martinez-Rivera, M., & Siddik, Z. H. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.026 · Cited by 80
Zhou, F., Zhu, L., Wang, K., & Murray, M. T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.004 · Cited by 80
Li, X., Lin, Z., Zhang, B., Guo, L., Liu, S., Li, H., Zhang, J., & Ye, Q. (2016) · Scientific Reports · doi:10.1038/srep21010 · Cited by 79
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance
Ramadoss, S., Sen, S., Ramachandran, I., Roy, S., Chaudhuri, G., & Farias‐Eisner, R. (2016) · Oncogene · doi:10.1038/onc.2016.320 · Cited by 78
Meng, Y., Chen, C., Yung, M. M. H., Sun, W., Sun, J. F., Li, Z., Li, J., Li, Z., Zhou, W., Liu, S. S., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.029 · Cited by 78
The Role of Ubiquitination in the Direct Mitochondrial Death Program of p53
Marchenko, N. D., & Moll, U. M. (2007) · Cell Cycle · doi:10.4161/cc.6.14.4503 · Cited by 76
MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1
Zhang, Y., Xu, W., Ni, P., Li, A., Zhou, J., & Xu, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16529 · Cited by 75
Self-citationZarogoulidis, P., Petanidis, S., Kioseoglou, E., Domvri, K., Anestakis, D., & Zarogoulidis, P. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.04.009 · Cited by 74
Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy
Ma, B., Yuan, Z., Zhang, L., Lv, P., Yang, T., Gao, J., Pan, N., Wu, Q., Lou, J., Han, C., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.008 · Cited by 74
ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells
Xu, Y., Gao, W., Zhang, Y., Wu, S., Liu, Y., Deng, X., Xie, L., Yang, J., Yu, H., Su, J., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4476 · Cited by 74
Yang, H., Ma, Y., Zhou, Y., Xu, L., Chen, X., Ding, W., & Zou, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.045 · Cited by 73
Blair, B. G., Larson, C., Adams, P. L., Abada, P., Pesce, C. E., Safaei, R., & Howell, S. B. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068411 · Cited by 72
Somasagara, R. R., Spencer, S. M., Tripathi, K. K., Clark, D. W., Mani, C., da Silva, L. M., Scalici, J. M., Kothayer, H., Westwell, A. D., Rocconi, R. P., et al. (2017) · Oncogene · doi:10.1038/onc.2017.279 · Cited by 72
Martinez‐Balibrea, E., Martínez‐Cardús, A., Musulén, E., Ginés, A., Manzano, J. L., Aranda, E., Plasencia, C., Neamati, N., & Abad, A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24273 · Cited by 71
Xiao, M., Cai, J., Cai, L., Jia, J., Xie, L., Zhu, Y., Huang, B., Jin, D., & Wang, Z. (2017) · Journal of Ovarian Research · doi:10.1186/s13048-017-0321-8 · Cited by 71
Chisholm, C. L., Wang, H., Wong, A. H., Vázquez-Ortíz, G., Chen, W., Xu, X., & Deng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12992 · Cited by 69
Self-citationSong, L., Li, Y., Li, W., Wu, S., & Li, Z. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24665 · Cited by 68
'BRCAness' and its implications for platinum action in gynecologic cancer.
Muggia, F. M., & Safra, T. (2014) · PubMed · Cited by 68
Bompiani, K. M., Tsai, C., Achatz, F. P., Liebig, J. K., & Howell, S. B. (2016) · Metallomics · doi:10.1039/c6mt00076b · Cited by 68
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
Ahmed, E. M., Bandopadhyay, G., Coyle, B., & Grabowska, A. M. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0374-8 · Cited by 67
KLF5 mediates vascular remodeling via HIF-1α in hypoxic pulmonary hypertension
Li, X., He, Y., Xu, Y., Huang, X., Liu, J., Xie, M., & Liu, X. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2015 · Cited by 65
Self-citationZhang, L., Wang, Y., Li, X., Xia, X., Li, N., He, R., He, H., Han, C., & Zhao, W. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.008 · Cited by 65
Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways
Masters, J. R., Thomas, R., Hall, A. G., Hogarth, L., Matheson, E. C., Cattan, A. R., & Lohrer, H. D. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00033-0 · Cited by 64
Sui, C., Meng, F., Li, Y., & Jiang, Y. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0488-y · Cited by 64
Graf, N., Ang, W. H., Zhu, G., Myint, M., & Lippard, S. J. (2011) · ChemBioChem · doi:10.1002/cbic.201000724 · Cited by 64
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin
Huang, C. P., Fofana, M., Chan, J., Chang, C. J., & Howell, S. B. (2014) · Metallomics · doi:10.1039/c3mt00331k · Cited by 63
Zhou, P., Ma, L., Zhou, J., Jiang, M., Rao, E., Zhao, Y., & Guo, F. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3392 · Cited by 62
Self-citationMiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1
Liu, Y., Niu, Z., Lin, X., & Tian, Y. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.6 · Cited by 62
Liu, C., Hua, K., Li, K., Kao, H., Hong, R., Ko, J., Hsiao, M., Kuo, M., & Tan, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0567-t · Cited by 62
Wang, S., Wung, C.-H., Chen, M.-S., Chen, C., Yin, P., Yeh, T.-S., Chang, Y.-L., Chou, Y., Hung, H.-H., & Lee, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113389 · Cited by 62
Zhu, X., Ji, M., Han, Y., Guo, Y., Zhu, W., Gao, F., Yang, X., & Zhang, C. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3873 · Cited by 61
JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells
Xu, W., Chen, Q., Wang, Q., Sun, Y., Wang, S., Li, A., Xu, S., Røe, O. D., Wang, M., Zhang, R., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.517 · Cited by 60
Self-citationmiR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1
Huang, H., Tang, J., Zhang, L., Bu, Y., & Zhang, X. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4593 · Cited by 60
Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes
Danford, A. J., Wang, D., Wang, Q., Tullius, T. D., & Lippard, S. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506025102 · Cited by 59
Habel, N., Hamidouche, Z., Girault, I., Patiño‐García, A., Lecanda, F., Marie, P. J., & Fromigué, O. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.405 · Cited by 58
Shi, L., Xu, Z., Wu, G., Chen, X., Huang, Y., Wang, Y., Jiang, W., & Ke, B. (2017) · BMC Cancer · doi:10.1186/s12885-017-3132-9 · Cited by 57
Safaei, R., Adams, P. L., Maktabi, M. H., Mathews, R. A., & Howell, S. B. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.02.016 · Cited by 56
Wang, N., Song, L., Xu, Y., Zhang, L., Wu, Y., Guo, J., Ji, W., Li, L., Zhao, J., Zhang, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.057 · Cited by 56
miR-634 Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity
Fujiwara, N., Inoue, J., Kawano, T., Tanimoto, K., Kozaki, K., & Inazawa, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0257 · Cited by 54
Wwox–Brca1 interaction: role in DNA repair pathway choice
Schrock, M. S., Batar, B., Lee, J., Druck, T., Ferguson, B. W., Cho, J. H., Akakpo, K. E., Hagrass, H. A., Heerema, N. A., Xia, F., et al. (2016) · Oncogene · doi:10.1038/onc.2016.389 · Cited by 54
Liu, W., Chen, H., Wong, N. W., Haynes, W., Baker, C. M., & Wang, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.025 · Cited by 53
Öhrvik, H., Logeman, B. L., Turk, B., Reinheckel, T., & Thiele, D. J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.731281 · Cited by 52
Fang, T., Chen, W., Sheng, Y., Yuan, S., Tang, Q., Li, G., Huang, G., Su, J., Zhang, X., Zang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08102-z · Cited by 51
Kong, L. R., Chua, K. N., Sim, W. J., Ng, H. C., Bi, C., Ho, J., Nga, M. E., Pang, Y. H., Ong, W. R., Soo, R. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0062 · Cited by 50
miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2
Chen, X., Zhang, Y., Shi, Y., Lian, H., TU, H., Han, S. H., Peng, B., Liu, W., & He, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3143 · Cited by 47
Sun, Y., Guan, Z., Liang, L., Cheng, Y., Zhou, J., Li, J., & Xu, Y. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3256 · Cited by 47
Self-citationChen, X., Jiang, Y., Huang, Z., Li, D., Chen, X. F., Cao, M., Meng, Q., Pang, H., Sun, L., Zhao, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep19455 · Cited by 47
Jiang, L., Zhang, Q., Ren, H., Ma, S., Lu, C., Liu, B., Liu, J., Liang, J., Li, M., & Zhu, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124994 · Cited by 45
Self-citationZhao, Y., Ma, K., Yang, S., Zhang, X., Wang, F., Zhang, X., Liu, H., & Fan, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4409 · Cited by 45
Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells
Åkerfeldt, M. C., Tran, C. M.-N., Shen, C., Hambley, T. W., & New, E. J. (2017) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-017-1467-y · Cited by 44
Fang, X., Li, Y., Wan, Y., & Xue, M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3548-1 · Cited by 44
Regulation ofOCT2transcriptional repression by histone acetylation in renal cell carcinoma
Zhu, Q., Yu, L., Qin, Z., Chen, L., Hu, H., Zheng, X., & Zeng, S. (2019) · Epigenetics · doi:10.1080/15592294.2019.1615354 · Cited by 42
Self-citationSomers, J., Wilson, L. A., Kilday, J., Horvilleur, E., Cannell, I. G., Pöyry, T. A. A., Cobbold, L. C., Kondrashov, A., Knight, J. R. P., Puget, S., et al. (2015) · Genes & Development · doi:10.1101/gad.261867.115 · Cited by 42
Zhao, L., Li, W., Zhou, Y., Zhang, Y., Huang, S., Xu, X., Li, Z., & Guo, Q. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.01.014 · Cited by 41
Hernández-Luna, M. A., Rocha‐Zavaleta, L., Vega, M. I., & Huerta‐Yépez, S. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.733874 · Cited by 41
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance
Zhou, W., Sun, W., Yung, M. M. H., Dai, S., Cai, Y., Chen, C., Meng, Y., Lee, J. B., Braisted, J. C., Xu, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0238-8 · Cited by 41
Myint, K. N., Li, Y., Paxton, J. W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130727 · Cited by 40
Pan, C., Jin, L., Wang, X., Li, Y., Chun, J., Boese, A. C., Li, D., Kang, H., Zhang, G., Zhou, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124550 · Cited by 39
Lee, J., Chae, J.-W., Kim, J. K., Kim, H. J., Chung, J. Y., & Kim, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.015 · Cited by 38
Wu, B., Cui, J., Yang, X.-M., Liu, Z., Song, F., Li, L., Jiang, J., & Chen, Z. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.251 · Cited by 38
Oien, D. B., Garay, T., Eckstein, S., & CHIEN, J. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00970 · Cited by 37
Hernández-Valencia, J. A., García-Villa, E., Arenas-Hernández, A., García-Mena, J., Díaz‐Chávez, J., & Gariglio, P. (2018) · Nutrients · doi:10.3390/nu10091148 · Cited by 37
Kemp, S. R. M., Brink, A., van der Meulen, I. H., de Menezes, R. X., Beest, D. E. T., Leemans, C. R., van Beusechem, V. W., Braakhuis, B. J. M., & Brakenhoff, R. H. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0457 · Cited by 36
The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy
Chen, J., Solomides, C., Simpkins, F. A., & Simpkins, H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3225-1 · Cited by 36
miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells
Pannuru, P., Dontula, R., Khan, A., Engelhard, H. H., Ozer, H., Chetty, C., & Lakka, S. S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.06.014 · Cited by 35
The African-specific S47 polymorphism of p53 alters chemosensitivity
Basu, S., Barnoud, T., Kung, C.-P., Reiss, M., & Murphy, M. E. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1215390 · Cited by 35
Enhancement of Drug Sensitivity by Knockdown of HIF-1α in Gastric Carcinoma Cells
Zhao, Q., Tan, B., Li, Y., Fan, L.-Q., Yang, P., & Tian, Y. Y. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504015x14500513118029 · Cited by 33
Cited by
Linares, J., Sallent-Aragay, A., Badia-Ramentol, J., Recort-Bascuas, A., Méndez, A., Manero-Rupérez, N., Re, D. L., Rivas, E. I., Guiu, M., Zwick, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36334-1 · Cited by 109
Hartmann, J., Henschel, N., Bartmann, K., Dönmez, A., Brockerhoff, G., Koch, K., & Fritsche, E. (2023) · Cells · doi:10.3390/cells12091270 · Cited by 31
AAontology: An Ontology of Amino Acid Scales for Interpretable Machine Learning
Breimann, S., Kamp, F., Steiner, H., & Frishman, D. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168717 · Cited by 15
Regulation of astrocyte metabolism by mitochondrial translocator protein 18 kDa
Firth, W., Robb, J. L., Stewart, D., Pye, K. R., Bamford, R., Oguro‐Ando, A., Beall, C., & Ellacott, K. L. J. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16089 · Cited by 5
Metadata
- Authors
- Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., & Yu, L.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-03-20
- Volume
- 11
- Pages
- 343-343
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3010974323
- Cited by
- 479
- References
- 224
- FWCI
- 21.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.